

World Journal of *Clinical Cases*

World J Clin Cases 2023 May 16; 11(14): 3114-3368



Contents

Thrice Monthly Volume 11 Number 14 May 16, 2023

OPINION REVIEW

- 3114 Modernising autism spectrum disorder model engineering and treatment *via* CRISPR-Cas9: A gene reprogramming approach

Sandhu A, Kumar A, Rawat K, Gautam V, Sharma A, Saha L

REVIEW

- 3128 Burden of disability in type 2 diabetes mellitus and the moderating effects of physical activity

Oyewole OO, Ale AO, Ogunlana MO, Gurayah T

MINIREVIEWS

- 3140 Postoperative hypoxemia for patients undergoing Stanford type A aortic dissection

Liu HY, Zhang SP, Zhang CX, Gao QY, Liu YY, Ge SL

ORIGINAL ARTICLE

Case Control Study

- 3148 Impact of extended nursing model after multi-disciplinary treatment on young patient with post-stroke

Xu XY, Pang ZJ, Li MH, Wang K, Song J, Cao Y, Fang M

- 3158 Changes and significance of serum ubiquitin carboxyl-terminal hydrolase L1 and glial fibrillary acidic protein in patients with glioma

Zhu QH, Wu JK, Hou GL

Retrospective Study

- 3167 Multitrack and multianchor point screw technique combined with the Wiltse approach for lesion debridement for lumbar tuberculosis

Yuan YF, Ren ZX, Zhang C, Li GJ, Liu BZ, Li XD, Miao J, Li JF

- 3176 Clinical features and prognostic factors in 49 patients with follicular lymphoma at a single center: A retrospective analysis

Wu H, Sun HC, Ouyang GF

- 3187 Value of optical coherence tomography measurement of macular thickness and optic disc parameters for glaucoma screening in patients with high myopia

Mu H, Li RS, Yin Z, Feng ZL

Observational Study

- 3195 Comparative study of the clinical efficacy of all-inside and traditional techniques in anterior cruciate ligament reconstruction

An BJ, Wang YT, Zhao Z, Wang MX, Xing GY

- 3204** Positioning and design by computed tomography imaging in neuroendoscopic surgery of patients with chronic subdural hematoma

Wang XJ, Yin YH, Zhang LY, Wang ZF, Sun C, Cui ZM

- 3211** Evaluation of chronic idiopathic tinnitus and its psychosocial triggers

Hamed SA, Attiah FA, Fawzy M, Azzam M

- 3224** Intestinal complications in patients with Crohn's disease in the Brazilian public healthcare system between 2011 and 2020

Sasaki LY, Martins AL, Galhardi-Gasparini R, Saad-Hossne R, Ritter AMV, Barreto TB, Marcolino T, Balula B, Yang-Santos C

Randomized Controlled Trial

- 3238** Effect of non-pharmacological treatment on the full recovery of social functioning in patients with attention deficit hyperactivity disorder

Lv YB, Cheng W, Wang MH, Wang XM, Hu YL, Lv LQ

CASE REPORT

- 3248** Diagnosis of tuberculous uveitis by the macrogenome of intraocular fluid: A case report and review of the literature

Zhang YK, Guan Y, Zhao J, Wang LF

- 3256** Intragastric fish bones migrate into the liver: A case report

Dai MG, Zheng JJ, Yang J, Ye B

- 3261** Primary seminal vesicle adenocarcinoma with a history of seminal vesicle cyst: A case report and review of literature

Yao Y, Liu S, He YL, Luo L, Zhang GM

- 3267** Immune checkpoint inhibitor therapy-induced autoimmune polyendocrine syndrome type II and Crohn's disease: A case report

Gao MJ, Xu Y, Wang WB

- 3275** Late-onset mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome with mitochondrial DNA 3243A>G mutation masquerading as autoimmune encephalitis: A case report

Wang JW, Yuan XB, Chen HF

- 3282** Metastatic gastric cancer from breast carcinoma presenting with paraneoplastic rheumatic syndrome: A case report

Rech MB, da-Cruz ER, Salgado K, Balbinot RA, Balbinot SS, Soldera J

- 3288** Novel mutation of SPG4 gene in a Chinese family with hereditary spastic paraplegia: A case report

Wang J, Bu WT, Zhu MJ, Tang JY, Liu XM

- 3295** Chronic pulmonary mucormycosis caused by rhizopus microsporus mimics lung carcinoma in an immunocompetent adult: A case report

Guo XZ, Gong LH, Wang WX, Yang DS, Zhang BH, Zhou ZT, Yu XH

- 3304** Idiopathic sclerosing mesenteritis presenting with small bowel volvulus in a patient with antiphospholipid syndrome: A case report
Chennavasini P, Gururatsakul M
- 3311** *Neisseria mucosa* - A rare cause of peritoneal dialysis-related peritonitis: A case report
Ren JM, Zhang XY, Liu SY
- 3317** Rectal prolapse in a 30-year-old bladder stone male patient: A case report
Ding HX, Huang JG, Feng C, Tai SC
- 3323** Successful treatment of veno-arterial extracorporeal membrane oxygenation complicated with left ventricular thrombus by intravenous thrombolysis: A case report
Wang YD, Lin JF, Huang XY, Han XD
- 3330** Successful remimazolam sedation-epidural block in an older patient with severe chronic obstructive pulmonary disease: A case report
Yu JJ, Pei HS, Meng Y
- 3340** *De novo* mutation of NAXE (APOA1BP)-related early-onset progressive encephalopathy with brain edema and/or leukoencephalopathy-1: A case report
Ding L, Huang TT, Ying GH, Wang SY, Xu HF, Qian H, Rahman F, Lu XP, Guo H, Zheng G, Zhang G
- 3351** Iatrogenic atlantoaxial rotatory subluxation after thyroidectomy in a pediatric patient: A case report
Hong WJ, Lee JK, Hong JH, Han MS, Lee SS
- 3356** Bladder metastasis from epidermal growth factor receptor mutant lung cancer: A case report
Jin CB, Yang L
- 3362** Primary rectal mucosa-associated lymphoid tissue lymphoma treated with only endoscopic submucosal dissection: A case report
Lee WS, Noh MG, Joo YE

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Jaw-Yuan Wang, MD, PhD, Professor, Surgical Oncologist, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan. jawyuanwang@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yin; Production Department Director: Xu Guo; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

May 16, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Retrospective Study

Clinical features and prognostic factors in 49 patients with follicular lymphoma at a single center: A retrospective analysis

Hao Wu, Hui-Cong Sun, Gui-Fang Ouyang

Specialty type: Hematology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Klapper W, Germany;
Shimokawa T, Japan

Received: February 27, 2023

Peer-review started: February 27, 2023

First decision: March 10, 2023

Revised: March 24, 2023

Accepted: April 12, 2023

Article in press: April 12, 2023

Published online: May 16, 2023



Hao Wu, Gui-Fang Ouyang, Department of Hematology, Ningbo First Hospital, Ningbo 315010, Zhejiang Province, China

Hui-Cong Sun, Adult Internal Medicine, Ningbo Women and Children's Hospital, Ningbo 315012, Zhejiang Province, China

Corresponding author: Gui-Fang Ouyang, MD, Chief Physician, Department of Hematology, Ningbo First Hospital, No. 59 Liuting Street, Ningbo 315010, Zhejiang Province, China.
oyguifangoy@163.com

Abstract

BACKGROUND

Follicular lymphoma (FL) is a type of B-cell lymphoma that originates at the germinal center and has a low malignancy rate. FL has become the most common inert lymphoma in Europe and America but has a relatively low incidence in Asia.

AIM

To explore the clinical features, curative effects, and prognostic factors of FL.

METHODS

Completed medical records of 49 patients with FL who were admitted to the Ningbo First Hospital from June 2010 to June 2021 were examined. These patients were definitively diagnosed by pathological biopsy or immunohistochemical staining. The diagnostic criteria were based on the 2008 World Health Organization classification of lymphomas. Ann Arbor staging was performed according to the imaging and bone marrow examination results. Risk stratification of all patients was performed based on the International Prognostic Index (IPI), age-adjusted IPI, Follicular Lymphoma International Prognosis Index (FLIPI), and FLIPI2 to compare the efficacy of different treatment regimens and analyze the related prognostic factors.

RESULTS

The age of onset in patients ranged from 24 to 76 years, with a median age of 51 years. Most patients developed the disease at 40–59 years of age, and the male:female ratio was 1.6:1. No significant difference was noted in the curative effect between the non-chemotherapy, combined chemotherapy, and other chemotherapy regimens ($P > 0.05$). Hemoglobin (Hb) level < 120 g/L, Ki-67 value $> 50\%$, bone marrow involvement, and clinical stages III–IV were associated with

a poor prognosis of FL ($P < 0.05$). However, the influence of other indicators was not statistically significant. Risk grouping was performed using the FLIPI, and the results showed that 24.5%, 40.8%, and 34.7% of patients were in the low-, moderate-, and high-risk groups, respectively. According to the survival analysis results, the survival rate of patients was lower in the high-risk group than in the other low-risk and moderate-risk groups ($P < 0.05$).

CONCLUSION

FL mainly occurs in middle-aged and elderly men, primarily affecting lymph nodes and bone marrow. Hb level, Ki-67 value, bone marrow involvement, and clinical staging were used to evaluate prognosis.

Key Words: Follicular lymphoma; Clinical feature; Curative effect; Prognosis; Survival analysis; Follicular Lymphoma International Prognosis Index

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Follicular lymphoma (FL) is a B-cell lymphoma originating from the germinal center and has a low malignancy rate. Completed medical records of 49 patients with follicular lymphoma admitted from June 2010 to June 2021 were retrospectively reviewed. FL was more common in middle-aged and elderly men than in women, mainly involving the lymph nodes and bone marrow. However, an optimal treatment strategy remains unclear. Hemoglobin levels, Ki-67 values, bone marrow involvement, and clinical stage can be used to evaluate prognosis.

Citation: Wu H, Sun HC, Ouyang GF. Clinical features and prognostic factors in 49 patients with follicular lymphoma at a single center: A retrospective analysis. *World J Clin Cases* 2023; 11(14): 3176-3186

URL: <https://www.wjgnet.com/2307-8960/full/v11/i14/3176.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v11.i14.3176>

INTRODUCTION

Follicular lymphoma (FL) is a B-cell lymphoma derived from the germinal center of follicles with the genetic hallmark t (14; 18) (q32; q21). Characterized by a low malignancy rate, FL has become the most common inert lymphoma in Europe and America, accounting for approximately 22% of non-Hodgkin lymphomas (NHL)[1]. In contrast, the incidence of FL in Asia is relatively low[2]. For example, patients with FL in China accounted for approximately 6%-10% of all NHL patients in 2008-2010 period[3]. To provide deep insights into the clinical features, curative effects, and prognostic factors of FL in China and to provide guidance for clinical diagnosis and treatment, this retrospective analysis aimed to examine the clinical data, such as clinical features, curative effects, and prognostic survival factors, of patients with FL who were diagnosed and treated at our hospital in recent years. Through this study, we aim to improve the understanding of this disease among clinicians and assist with diagnosis and treatment in clinical practice.

MATERIALS AND METHODS

Clinical data

Completed medical records of 49 patients with FL who were admitted to the Ningbo First Hospital from June 2010 to June 2021 were collected. These patients were definitively diagnosed by pathological biopsy or immunohistochemical staining. The diagnostic criteria were based on the 2008 World Health Organization (WHO) classification of lymphomas[4]. Ann Arbor staging was performed according to the imaging and bone marrow examination results. Risk stratification was performed for all patients based on the International Prognostic Index (IPI), age-adjusted IPI, Follicular Lymphoma International Prognosis Index (FLIPI), and Follicular Lymphoma International Prognosis Index 2 (FLIPI2)[5,6]. Medical follow-up was conducted through hospitalization, outpatient services, or telephone calls from the date of diagnosis to June 2021. After completing all treatments, patients in the remission stage [Complete remission (CR) + Partial remission (PR)] were followed up once every 2-3 mo in the first 2 years and once every 6 mo thereafter. The extent of follow-up was mainly determined according to the treatment of the patient at the onset of FL and related abnormal laboratory examination findings.

Observation indicators

General indicators: The clinical data of 49 patients with FL were retrospectively analyzed. These included age, sex, initial site of FL, the presence or absence of B symptoms, number of extralymphatic involvement sites, hepatomegaly, and splenomegaly.

Laboratory indicators: These indicators included hemoglobin (Hb) level, platelet count (PLT), white blood cell (WBC) count, absolute lymphocyte (LYM) count, albumin (ALB) level, globulin (GLB) level, lactate dehydrogenase (LDH) level, hydroxybutyrate dehydrogenase (HBDH) level, β 2-microglobulin (β 2-MG) level, immune phenotype, pathological grade, and Ki-67 value.

Clinical stage: All patients underwent computed tomography (CT) and bone marrow biopsy, and clinical staging was performed based on the Ann Arbor standards.

Survival and prognostic indicators: Survival time, overall survival (OS), progression-free survival (PFS), and related prognostic factors (such as age, pathological grade, clinical stage, LDH level, Hb level, and Ki-67 value) were analyzed.

Therapeutic scheme

The initial therapeutic schemes were classified as follows: Scheme I involved specifically targeted therapy without combined chemotherapy, including rituximab combined with lenalidomide in 10 patients and single-agent lenalidomide or rituximab in 4 patients (total: 14 patients); Scheme II involved rituximab combined with chemotherapy regimen, including rituximab or lenalidomide. Combined cyclophosphamide + doxorubicin + vincristine + prednisone (CHOP) regimen was administered to 30 patients, and rituximab-combined cyclophosphamide + vincristine + prednisone (COP) regimen was administered to 2 patients (total: 32 patients); Scheme III involved other regimens, including rituximab plus bortezomib combined with CHOP regimen in 2 patients and an FC (fluorouracil + cyclophosphamide) regimen in 1 patient, and was not included in the comparison of curative effects. The drug doses in all schemes were calculated based on the standard dose and body surface area.

Curative effect evaluation

The short-term curative effect was evaluated according to the evaluation criteria for malignant lymphomas, including CR, PR, stable disease (SD), and progressive disease (PD), while CR + PR constituted the objective remission rate.

The patients were evaluated once every two regular chemotherapy sessions with respect to curative effects and then re-evaluated after every two courses of treatment. Patients were classified based on CR, unconfirmed complete remission (CRu), PR, SD, PD, and relapse (those who reached CR/CRu in the early stages). Patients who met the first three criteria were regarded to have effective samples, whereas those meeting the remaining criteria were regarded to have ineffective samples.

Statistical analysis

Statistical analyses were performed using SPSS version 25.0. Data with normal distribution are presented as mean $\pm$ SD, and data with non-normal distribution are presented as median. Fisher's exact probability method was used to compare the curative effects of the different schemes. Survival data and prognosis were analyzed using the Kaplan-Meier method, and survival rates were compared using the log-rank test. Survival time, OS, PFS, and related prognostic factors (such as age, pathological grade, clinical stage, regular indicators, and Ki-67 value) were analyzed. $P < 0.05$ indicated statistically significant difference for all tests.

RESULTS

Basic data

The clinical data of 49 patients with FL were retrospectively analyzed, and the clinical characteristics, efficacy, prognosis, and survival factors were analyzed to improve the clinicians' understanding of this disease and provide guidance for clinical diagnosis and treatment.

Follow up results: Loss to follow-up (LTFU) was noted in three patients (LTFU rate: 6.1%), with a median follow-up time of 52 (2–85) mo.

Sex and age: Among the 49 patients, 30 (61.2%) were male and 19 (38.8%) were female patients, with male:female ratio of 1.6:1. The age at disease onset ranged from 24 to 76 years, with a median age of 51 years [17 (34.7%) patients aged > 60 years and 32 (65.3%) patients aged ≤ 60 years]. Overall, approximately 51% ($n = 25$) developed the disease between 40 and 59 years of age.

Pathological grade and clinical stage: The pathological grade and clinical stage of the 49 patients were determined according to the 2008 WHO classification of lymphomas and the Ann Arbor staging

standard. Eventually, 3 (6.1%) patients had Grade I FL, 16 (32.7%) had Grade II FL, and 30 (61.2%) had Grade III FL. In addition, 17 (34.7%) patients had Stage I FL, 32 (65.3%) had Stage II–III FL, and 31 (63.3%) had B symptoms. Among patients with Stage III–IV FL, 19 (59.4%) had B symptoms, 20 (40.9%) had anemia (Hb level < 120 g/L), 6 (18.8%) had PLT count $\leq 80 \times 10^9/L$, 24 (75.0%) had LYM count $> 1 \times 10^9/L$, and 29 (90.6%) had increased LDH level.

Clinical features

Initial site and extra-lymphatic involvement: Overall, 35 patients (71.4%) initially presented with enlarged lymph nodes and 14 (28.6%) initially presented with extralymphatic involvement. Among those initially presenting with extralymphatic involvement, the symptoms included an enlarged abdominal mass, splenomegaly, enlarged leg mass, enlarged tonsils, gastrointestinal tract involvement, and bone marrow involvement. Overall, 19 patients (38.8%) had extralymphatic node tissue or organ involvement, including 10 (20.4%) patients with bone marrow involvement, which was confirmed by clinical imaging such as endoscopy and CT and pathological biopsy results.

Hepatosplenomegaly: Based on physical examination and imaging data of the whole cohort, 2 (4.1%) patients had hepatomegaly and 10 (31.3%) had splenomegaly, including 3 patients with megalosplenitis.

Laboratory examination results

Blood routine examination: Overall, 20 (40.6%) patients had anemia (Hb level = 93 ± 4 g/L), 6 (18.8%) had PLT count $\leq 80 \times 10^9/L$ (median, $65 \times 10^9/L$), 11 (22.4%) had leukopenia (median WBC count, $4.0 \times 10^9/L$), 7 (14.3%) had leukocytosis (median WBC count, $10.0 \times 10^9/L$), and 24 (75.0%) had LYM count $> 1 \times 10^9/L$ (median, $1.97 \pm 0.67 \times 10^9/L$).

Biochemical indicators: There were 6 (12.4%) patients with decreased ALB level, 5 (10.2%) had increased GLB level, and 35 (71.4%) had increased LDH level (median, 317 IU/L).

Immune phenotypes: Among the 49 patients, B-cell-related common antigen CD20+ was expressed in 44 patients (89.8%), Bcl-2+ in 25 (51.0%) patients, Bcl-6+ in 32 (65.3%) patients, and CD10+ in 35 (71.4%) patients. The Ki-67 value was measured in the pathological specimens of 39 patients, with the results ranging from 5% to 90% (median, 30%). The Ki-67 value was $\leq 50\%$ in 27 (55.1%) patients and $> 50\%$ in 22 (44.9%) patients.

Other indicators: Among the 49 patients, β_2 -MG was detected in 47 patients, including 22 patients (46.8%) with increased β_2 -MG level (median, 3.33 mg/L).

Curative effects and influencing factors

Curative effects: Among the 49 patients, the effective rate was 50.0% for patients with Scheme I (7/14), 75.0% for patients with Scheme II (24/32), and 100% for patients undergoing Scheme III (3/3). The results of the Fisher's exact test showed no significant differences in curative effects between the three schemes ($P > 0.05$) (Table 1).

The influence of different factors on the curative effect: The analysis results of the influence of various factors on the curative effect showed that anemia could affect the curative effect; hence, it was identified as an independent influencing factor. Among the 13 patients with anemia, 6 (46.2%) patients had CR+PR, while among 36 patients without anemia, 26 (72.2%) had CR + PR. Fisher's exact test results showed that the effective treatment rate was higher in patients without anemia than in patients with anemia ($P < 0.05$). Sex, age, B symptoms, involvement of more than four lymph nodes, pathological grade, clinical stage, bone marrow involvement, hepatomegaly, splenomegaly, increased LYM count, thrombocytopenia, leukopenia, increased LDH level, increased β_2 -MG level, and other indicators had no significant influence on the curative effect ($P > 0.05$).

Survival and prognosis analysis

Survival analysis: All patients were followed up *via* telephone (follow-up time was calculated from the end of the last hospitalization to October 2020), with a median follow-up period of 52 (2–85) mo. The overall median survival was 41 mo in the 49 patients, while the 3-year and 5-year OS was 81.6% and 62.3%, respectively. The 3-year and 5-year PFS was 71.4% and 40.8%, respectively. According to the risk stratification (low-, moderate-, and high-risk groups) and analysis results of the five FLIPI-based adverse prognostic factors (age > 60 years, stages III–IV, involvement of more than four lymph nodes, Hb level < 120 g/L, and increased LDH level) affecting the survival rate, the survival rate was significantly lower ($P < 0.05$) in the high-risk group than in the other two groups. However, no significant difference was noted in the survival rate between the low- and moderate-risk groups ($P > 0.05$) (Table 2). The survival and total survival curves for the three risk groups are shown in Figure 1.

Prognostic analysis: Univariate analysis showed that anemia, a Ki-67 value $> 50\%$, bone marrow involvement, and clinical stages III–IV were the factors inducing a poor prognosis ($P < 0.05$). No

Table 1 Comparison of curative effects among different schemes, <i>n</i> (%)						
Scheme	Number of cases	CR	PR	SD	PD	ORR (%)
I	14	3 (21.4)	4 (28.6)	5 (35.7)	2 (14.3)	50.0
II	32	11 (34.4)	13 (40.6)	3 (9.4)	5 (15.6)	75.0
III	3	1 (33.3)	2 (66.7)	0	0	100.00

CR: Complete remission; PR: Partial remission; SD: Stable disease; PD: Progressive disease; ORR: Objective remission rate.

Table 2 Correlation survival analysis of different risk groups, <i>n</i> (%)						
Group	Risk factors	Cases, <i>n</i> (%)	3-year OS, % (SE)	3-year PFS, % (SE)	5-year OS, % (SE)	5-year PFS, % (SE)
Low risk	0-1	12 (24.5)	100	75.0 (0.18)	83.3 (0.12)	75.0 (0.18)
Medium risk	2	20 (40.8)	90.0 (0.08)	75.0 (0.08)	85.0 (0.11)	70.0 (0.16)
High risk	≥ 3	17 (34.7)	76.5 (0.10)	47.1 (0.13)	47.1 (0.13)	23.6 (0.20)

P < 0.05 compared with the other two groups. SE: Standard error; OS: Survival time; PFS: Progression-free survival.




Figure 1 Survival curve and total survival curve of different risk groups.

significant difference was noted in the prognosis between sex, age, B symptoms, pathological grade, number of involved lymph nodes, hepatosplenomegaly, decreased ALB level, leukopenia, increased GLB level, increased LDH level, leukocytosis, increased LYM count, increased β 2-MG level, immune phenotype expression (CD10+, Bcl-2+, and Bcl-6+), and other factors (*P* > 0.05) (Table 3). The survival curves of the four adverse factors affecting prognosis are shown in Figure 2.

DISCUSSION

FL is an inert NHL originating from the germinal center of follicles in the lymph nodes. Although individuals of any age can develop this disease, it is more common in adults, particularly men[1]. In this study, the peak age at FL onset ranged from 40 to 59 years, with a median age of 51 years, and the male:female ratio was 1.6:1. Initial lymph node enlargement was the most common clinical feature. However, nearly half of the patients with FL had extralymphatic and organ involvement. The most commonly affected sites include the liver, spleen, bone marrow, and gastrointestinal tract[2-4]. In this study, 31.3% of the patients had splenomegaly, 20.4% had bone marrow involvement, 4.1% had hepatomegaly, and 4.1% had gastrointestinal tract involvement, similar to findings of other reports China and

Table 3 Clinical features and univariate prognosis of 49 patients with follicular lymphoma

Factors	3-year OS, % (SE)	5-year OS, % (SE)	Log-rank (<i>P</i> value)
Sex			
M (30)	86.7 (0.05)	63.3 (0.09)	0.185
F (19)	78.9 (0.09)	63.1 (0.13)	
Age (yr)			
≤ 60 (32)	84.3 (0.05)	71.9 (0.08)	0.584
> 60 (17)	82.4 (0.08)	70.6 (0.13)	
The presence or absence of B symptoms			
Y (31)	77.4 (0.08)	58.1 (0.13)	0.237
N (18)	88.9 (0.06)	72.2 (0.09)	
Stage			
I-II (17)	94.1 (0.05)	94.1 (0.05)	0.043
III-IV (32)	78.1 (0.06)	65.6 (0.10)	
Pathological grading			
I (3)	100.0	100.0	0.321
II (16)	87.5 (0.07)	68.7 (0.12)	
III (30)	80.0 (0.05)	73.3 (0.11)	
BM infiltration			
Y (10)	70.0 (0.13)	30.0 (0.15)	0.007
N (39)	89.7 (0.04)	79.5 (0.08)	
Involved lymph node area			
≤ 4 (36)	86.1 (0.05)	72.2 (0.08)	0.054
> 4 (13)	76.9 (0.12)	53.8 (0.19)	
Hepatomegaly			
Y (2)	100.0	100.0	0.835
N (47)	85.1 (0.05)	74.4 (0.08)	
Splenomegaly			
Y (10)	80.0 (0.10)	60.0 (0.14)	0.169
N (39)	84.6 (0.05)	76.9 (0.09)	
LDH			
Normal (14)	85.7 (0.10)	71.4 (0.10)	0.312
High (35)	82.9 (0.05)	68.6 (0.09)	
Hb			
< 120 g/L (20)	75.0 (0.09)	45.0 (0.12)	0.011
≥ 120 g/L (29)	89.7 (0.04)	75.9 (0.09)	
WBC			
≤ 4 × 10 ⁹ /L (11)	100	72.7 (0.18)	0.481
> 4 × 10 ⁹ /L (38)	84.2 (0.05)	65.8 (0.08)	
WBC			
≤ 10 × 10 ⁹ /L (42)	88.1 (0.05)	66.7 (0.08)	0.813
> 10 × 10 ⁹ /L (7)	71.4 (0.21)	57.1 (0.21)	
LYM			

PLT	$\leq 1 \times 10^9/L$ (25)	80.0 (0.09)	68.0 (0.15)	0.494
	$> 1 \times 10^9/L$ (24)	87.5 (0.05)	66.7 (0.09)	
ALB	$\leq 80 \times 10^9/L$ (9)	100	66.7 (0.19)	0.998
	$> 80 \times 10^9/L$ (40)	82.5 (0.06)	70.0 (0.08)	
GLB	≤ 35 g/L (6)	83.3 (0.15)	66.7 (0.19)	0.941
	> 35 g/L (43)	87.4 (0.05)	67.2 (0.08)	
Ki-67	≤ 34 g/L (44)	87.9 (0.05)	66.5 (0.08)	0.758
	> 34 g/L (5)	80.0 (0.18)	80.0 (0.18)	
Bcl-6+	$\leq 50\%$ (27)	96.2 (0.04)	91.3 (0.06)	0.004
	$> 50\%$ (22)	83.3 (0.15)	31.2 (0.25)	
Bcl-6-	32	83.9 (0.07)	74.6 (0.09)	0.926
CD10+	17	100	68.6 (0.19)	
CD10-	35	85.7 (0.07)	64.6 (0.11)	0.293
Bcl-2+	14	90.9 (0.09)	90.9 (0.09)	
Bcl-2-	25	91.4 (0.06)	76.4 (0.09)	0.493
	24	80 (0.10)	66.7 (0.15)	

Statistical significance was set at $P < 0.05$. OS: Overall survival; Hb: Hemoglobin; PLT: Platelet; WBC: White blood cell; LYM: Lymphocyte; ALB: Albumin; GLB: Globulin; LDH: Lactate dehydrogenase; SE: Standard error.

abroad, with the exception of low hepatomegaly incidence[5].

The immune phenotype of FL is vital for its diagnosis and treatment. Bcl-2, Bcl-6, and CD10 expression has been detected in most patients[6,7]. In terms of the immune phenotype detection results of 40 patients, 51.0% of patients expressed Bcl-2+, 65.3% expressed Bcl-6+, and 71.4% expressed CD10+, which is lower than the data reported abroad[8,9], which may be related to the small size of this sample.

The FLIPI is an important prognostic tool for patients with FL before treatment. As revealed in an international multicenter study involving 4,167 FL patients, age (≤ 60 years or > 60 years), Ann Arbor stage (Stage I-II or Stage III-IV), Hb level (< 120 g/L or > 120 g/L), LDH level (normal or increased), and number of lymph node area involved (≤ 4 or > 4) could affect the prognosis of patients[4]. According to the findings of the present study, clinical stage, bone marrow involvement, Ki67 value, and decreased Hb level can affect the prognosis of patients; however, age, LDH level, and number of involved lymph node areas were not associated with the prognosis of patients, which may be associated with the small sample size of the study. Analysis of the three different risk groups based on the FLIPI score demonstrated that the 5-year OS and PFS of patients were significantly lower in the high-risk group than in the low-risk and moderate-risk groups, which is consistent with the results reported abroad[10,11].

As reported in some articles abroad, the positive expression of molecular biological markers such as Bcl-2 and Bcl-6 could affect the curative effect and prognosis of patients with FL[7,12]. However, the positive expression of Bcl-2 and Bcl-6 was not significantly correlated with the prognosis of patients in this study[13]. The Southwest Oncology Group has selected Ki-67 value as an early indicator to predict the clinical progression of tumors and an important parameter for identifying NHL prognosis[14]. In this study, a Ki-67 value of 50% was selected as the cutoff point, and the analysis showed that the 5-year OS of patients $> 50\%$ was significantly lower than OS of patients $\leq 50\%$, which is in line with the results of a previous study[15]. Therefore, Ki-67 Levels must be measured during pathological examinations.

Currently, there is no consensus on the therapeutic schemes for FL. With continuous exploration of the pathogenesis, clinical features, and prognosis of FL, rituximab has been confirmed as an important drug for treating FL, as it can improve the total remission rate and prolong the remission duration in patients[16,17]. In this study, 32 newly treated patients with FL received rituximab therapy in conjunction with chemotherapy, and the overall response rate was 75%, which was slightly higher than that (67%) reported elsewhere[18].




Figure 2 Survival curve of poor prognostic factors. A: Anemia; B: Bone marrow infiltration; C: Clinical stages; D: ki67.

Because of the long course of the disease, high relapse rate after remission, and strong tendency to transform into diffuse large B-cell lymphoma, it is difficult to employ conventional therapies to improve the quality of life and disease-free survival rate of patients with FL. The key molecules, proteins, and pathways expressed in the development of FL are expected to become new treatment targets, including CD20 antibody, PI3K inhibitor, BTK pathway inhibitor, immunomodulator, and anti-PD1. Among these, obinutuzumab has received much attention, with many studies demonstrating that obinutuzumab can significantly prolong PFS and OS in patients with FL and can even become a candidate to replace rituximab because it has been launched in the market and is widely used. These drugs provide additional therapeutic options for patients with FL, further improving the remission rate and prolonging the survival time of patients, all of which can be attributed to the progress of individualized treatment based on further risk stratification of FL.

CONCLUSION

FL mainly occurs in men aged 50–69 years who specifically present with lymph node involvement. Currently, most FL patients are treated with chemotherapy, and there is a lack of a standard therapeutic scheme. Rituximab combined with chemotherapy can improve the remission rate and prolong the survival time of patients with FL, and therapy integrating fludarabine is expected to become the first-line therapeutic scheme. Advanced clinical stage, high Ki-67 value, anemia, and bone marrow involvement affect the prognosis of patients with FL.

ARTICLE HIGHLIGHTS

Research background

Follicular lymphoma (FL) is a B-cell lymphoma that originates at the germinal center and has a low malignancy rate.

Research motivation

To gain a deeper understanding of the clinical characteristics, efficacy, and prognostic factors of FL in China and to provide guidance for clinical diagnosis and treatment, we retrospectively analyzed the clinical data of 49 patients with FL who were diagnosed and treated at our hospital in recent years.

Research objectives

This study aimed to explore the clinical features, curative effects, and prognostic factors of FL.

Research methods

The medical records of 49 patients with FL admitted to the Ningbo First Hospital from June 2010 to June 2021 were retrospectively reviewed to compare the curative effects of different therapeutic schemes and analyze the related prognostic factors.

Research results

The age at onset in the 49 patients ranged from 24 to 76 years, with a median age of 51 years. The male:female ratio was 1.6:1. No significant difference was noted in the curative effect between the non-chemotherapy, combined chemotherapy, and other chemotherapy regimen groups. Hemoglobin (Hb) level < 120 g/L, Ki-67 value >50%, bone marrow involvement, and clinical stages III-IV were associated with a poor prognosis. However, the influence of the other indicators on prognosis was not statistically significant. Risk grouping was performed using the Follicular Lymphoma International Prognosis Index. The results showed that 24.5%, 40.8%, and 34.7% of patients were in the low-, moderate-, and high-risk groups, respectively. According to the survival analysis results, the survival rate of patients was lower in the high-risk group than in the other two groups.

Research conclusions

FL mainly occurs in middle-aged or older men who mainly present with lymph node and bone marrow involvement. Hb level, Ki-67 value, bone marrow involvement, and clinical stage can be used for prognostic estimation.

Research perspectives

To analyze the clinical characteristics, efficacy, prognosis, and survival factors of 49 patients in order to improve clinicians' understanding of the disease and provide guidance for clinical diagnosis and treatment.

FOOTNOTES

Author contributions: Ouyang GF provided the experimental idea; Wu H and Sun HC collected, sorted, and analyzed the data; Wu H completed the writing of this article; and all authors have read and approved the final draft.

Supported by Zhejiang TCM Science and Technology Project, No. 2023ZL653.

Institutional review board statement: This study was approved by the Institutional Ethics Committee of Ningbo First Hospital.

Informed consent statement: Informed consent was obtained from the patients and their parents/guardians.

Conflict-of-interest statement: We have no financial relationships or any other conflict of interest to disclose.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Hao Wu 0000-0001-6847-6898; Hui-Cong Sun 0000-0003-2985-6251; Gui-Fang Ouyang 0000-0002-6428-0000.

S-Editor: Wang JL

L-Editor: A

P-Editor: Zhao S

REFERENCES

- 1 **Zelenetz AD**, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N. Non-Hodgkin's lymphomas. *J Natl Compr Canc Netw* 2011; **9**: 484-560 [PMID: [21550968](#) DOI: [10.6004/jnccn.2011.0046](#)]
- 2 **Gross SA**, Zhu X, Bao L, Ryder J, Le A, Chen Y, Wang XQ, Irons RD. A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China. *Int J Hematol* 2008; **88**: 165-173 [PMID: [18648906](#) DOI: [10.1007/s12185-008-0132-1](#)]
- 3 **Yang QP**, Zhang WY, Yu JB, Zhao S, Xu H, Wang WY, Bi CF, Zuo Z, Wang XQ, Huang J, Dai L, Liu WP. Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. *Diagn Pathol* 2011; **6**: 77 [PMID: [21854649](#) DOI: [10.1186/1746-1596-6-77](#)]
- 4 **Campo E**, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. *Blood* 2011; **117**: 5019-5032 [PMID: [21300984](#) DOI: [10.1182/blood-2011-01-293050](#)]
- 5 **Li Y**, Zhang Y, Wang W, Wei C, Zhao D, Zhang W. Follicular Lymphoma in China: Systematic Evaluation of Follicular Lymphoma Prognostic Models. *Cancer Manag Res* 2022; **14**: 1385-1393 [PMID: [35422658](#) DOI: [10.2147/CMAR.S349193](#)]
- 6 **Federico M**, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabatini E, McLaughlin P, Solal-Céligny P. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. *J Clin Oncol* 2009; **27**: 4555-4562 [PMID: [19652063](#) DOI: [10.1200/JCO.2008.21.3991](#)]
- 7 **Khanlari M**, Chapman JR. Follicular lymphoma: updates for pathologists. *J Pathol Transl Med* 2022; **56**: 1-15 [PMID: [34942689](#) DOI: [10.4132/jptm.2021.09.29](#)]
- 8 **Sakurai M**, Mori T, Kato K, Kanaya M, Mizuno S, Shiratori S, Wakayama T, Uchida N, Kobayashi H, Kubo K, Amano I, Ohta T, Miyazaki Y, Kanda J, Fukuda T, Atsuta Y, Kondo E; Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation. *Bone Marrow Transplant* 2021; **56**: 1462-1466 [PMID: [33514920](#) DOI: [10.1038/s41409-020-01192-8](#)]
- 9 **Zinzani PL**, Flinn IW, Yuen SLS, Topp MS, Rusconi C, Fleury I, Le Dû K, Arthur C, Pro B, Gritti G, Crump M, Petrich A, Samineni D, Sinha A, Punnoose EA, Szafer-Glusman E, Spielewoy N, Mobasher M, Humphrey K, Kornacker M, Hiddemann W. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. *Blood* 2020; **136**: 2628-2637 [PMID: [32785666](#) DOI: [10.1182/blood.2020005588](#)]
- 10 **Gordon MJ**, Smith MR, Nastoupil LJ. Follicular lymphoma: The long and winding road leading to your cure? *Blood Rev* 2023; **57**: 100992 [PMID: [35908982](#) DOI: [10.1016/j.blre.2022.100992](#)]
- 11 **Batlevi CL**, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Soumerai JD, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Kumar A, Matasar MJ, Moskowitz AJ, Moskowitz CH, Noy A, Owens C, Palomba LM, Straus D, von Keudell G, Zelenetz AD, Seshan VE, Younes A. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. *Blood Cancer J* 2020; **10**: 74 [PMID: [32678074](#) DOI: [10.1038/s41408-020-00340-z](#)]
- 12 **Dreyling M**, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M; ESMO Guidelines Committee. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2016; **27**: v83-v90 [PMID: [27664263](#) DOI: [10.1093/annonc/mdw400](#)]
- 13 **Maurer MJ**, Bachy E, Ghesquière H, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Allmer C, Chassagne-Clément C, Nicolas-Virelizier E, Sebban C, Lebras L, Sarkozy C, Macon WR, Feldman AL, Syrbu SI, Traverse-Glehan A, Coiffier B, Slager SL, Weiner GJ, Witzig TE, Habermann TM, Salles G, Cerhan JR, Link BK. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. *Am J Hematol* 2016; **91**: 1096-1101 [PMID: [27465588](#) DOI: [10.1002/ajh.24492](#)]
- 14 **Xu-Monette ZY**, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. *Blood* 2018; **131**: 68-83 [PMID: [29118007](#) DOI: [10.1182/blood-2017-07-740993](#)]
- 15 **Marcus R**, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Obinituzumab for the First-Line Treatment of Follicular Lymphoma. *N Engl J Med* 2017; **377**: 1331-1344 [PMID: [28976863](#) DOI: [10.1056/NEJMoa1614598](#)]
- 16 **Pastore A**, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, Van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberger D, Möller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. *Lancet Oncol* 2015; **16**: 1111-1122 [PMID: [26256760](#) DOI: [10.1016/S1470-2045\(15\)00169-2](#)]
- 17 **Casulo C**, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. *J Clin Oncol* 2015; **33**: 2516-2522 [PMID: [26124482](#) DOI: [10.1200/JCO.2014.59.7534](#)]
- 18 **Lesokhin AM**, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattray D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J. Nivolumab in Patients With Relapsed or Refractory Hematologic

Malignancy: Preliminary Results of a Phase Ib Study. *J Clin Oncol* 2016; **34**: 2698-2704 [PMID: [27269947](#) DOI: [10.1200/JCO.2015.65.9789](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

